The ALIA study (Antidepressant and Lithium Augmentation) is a pharmacogenetic study on the response prediction of lithium augmentation in unipolar depression. It is investigating whether there are genetic variants that lead to better or worse response to lithium augmentation.
Lithium augmentation is the addition of lithium salts to an antidepressant that has not been sufficiently effective alone. The efficacy of lithium augmentation in treatment-resistant depression is well established and is an approved treatment for depression. The aim of the study is to identify genetic markers that have predictive power for response to lithium augmentation (so-called response predictors). Knowledge of such factors could be incorporated into treatment decisions in the future and help improve therapy for depression. We offer patients who have not responded adequately to therapy with an antidepressant and are interested in participating in this scientific study the opportunity for treatment in the university outpatient clinic of the Department of Psychiatry and Psychotherapy of the Charité Campus Mitte.